5 Million Initiative To Enhance Care For Adults With Cystic Fibrosis
The Cystic Fibrosis Foundation has announced the launch of a new $5 million initiative to enhance care for the growing adult CF population. The initiative, called the Program for Adult Care Excellence (PACE), will expand the scope of adult care programs for people with cystic fibrosis.
Great Strides 2008 - Taking Steps To Cure Cystic Fibrosis, UK
Thousands of people will be taking steps to cure Cystic Fibrosis (CF) this year by taking part in a series of sponsored walks across the UK. Great Strides, sponsored by Solvay Healthcare, is a worldwide initiative to get people walking to help see off CF.
Positive Early Results For Phase 2 Clinical Trial Of VX-770 For Cystic Fibrosis
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Cystic Fibrosis Foundation Announces Positive Early Results For Phase 2 Clinical Trial Of VX-770 - An Oral Compound To Treat CF
The Cystic Fibrosis Foundation has announced that VX-770, an oral drug in development that targets a basic defect in CF, showed promising results in an ongoing Phase 2a clinical trial for patients who carry the G551D mutation of CF. The drug is being developed by Vertex Pharmaceuticals Incorporated.
Cystic Fibrosis In Mice
"Drug 'could aid cystic fibrosis'" is the headline on BBC News. The article says that "widely-used antidepressants could prevent infections which shorten the lives of many cystic fibrosis patients". The report is based on the findings from a study in mice which has shed further light on the biological processes involved in the changes to the lungs caused by the cystic fibrosis mutation.
KaloBios Initiates Phase 1 2 Trial Of Humaneered TM Monoclonal Antibody KB001 For Treatment Of Pseudomonas Infections In Cystic Fibrosis Patients
KaloBios Pharmaceuticals, Inc., a privately held biopharmaceutical company, announced the initiation of a Phase 1/2 clinical trial of KB001, a Humaneered™ , high-affinity antibody fragment that KaloBios is developing for the treatment of P.
Lung Transplants Not Dangerous For Children With Cystic Fibrosis, After All - Experts Say Recent Study Was Seriously Flawed
Responding to a study published in the New England Journal of Medicine, which concluded that lung transplants were harmful for children with cystic fibrosis, articles published in the latest issue of Pediatric Transplantation refute the conclusions and argue that the highly influential research was severely flawed.
Scientists Overcome Obstacle In Gene Therapy For Cystic Fibrosis, UK
Scientists from the UK CF Gene Therapy Consortium funded by the Cystic Fibrosis Trust have overcome a major obstacle in their ground-breaking gene therapy programme for Cystic Fibrosis. Cystic Fibrosis (CF) is the UK's most common life-threatening inherited disease and is caused by a single defective gene.
Technique For Early Detection Of Superbug Superbug Pseudomonas Aeruginosa Which Particularly Infects Cystic Fibrosis Patients
A team of researchers led by University of Sunderland scientists has made a major breakthrough in the fight against a deadly hospital infection which kills tens of thousands of people every year. Experts have discovered a technique for the early detection of the superbug pseudomonas aeruginosa which particularly infects patients with cystic fibrosis.
Debate At ISHLT: Lung Transplants In Cystic Fibrosis Patients With Life-Threatening Bacteria
During the Satellite Symposium 3: The Challenges of Lung Transplantation in Cystic Fibrosis (CF) at the International Society of Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, clinicians and researchers discussed some of the unique challenges in achieving excellent lung transplant outcomes in patients with CF.